Comparing Vardenafil to Other PDE5 Inhibitors

Dr. E. U. Krohn Hamburg, 22177, Germany Completed Praxis Hr. Dr. F.

• Psychological effects like anxiety may influence response.
• Partner communication can improve treatment outcomes.
• Stress reduction techniques may complement medication.

Matthes Leisnig, 04703, Germany Completed Praxis Fr. Dr. W. Pohl Dresden, 01129, Germany Completed Praxis Drs. Careggi Firenze, 50139, Italy Completed Hospital Policlínico de Vigo - Clínica Povisa Vigo, 36211, Spain Completed Hospital Universitario de Canarias La Laguna, 38320, Spain Completed Hospital General Universitario de Alicante Alicante, 03010, Spain Completed Hospital Fundació Puigvert Barcelona, 08025, Spain Completed CAP Sarrià Barcelona, 08034, Spain Completed CHU de Liège LIEGE, 4000, Belgium Completed Dr Bongaerts - Dr Denier GENK, 3600, Belgium Completed Medisch Spectrum Twente, Locatie Ariensplein ENSCHEDE, 7511 JX, Netherlands Completed Deventer Ziekenhuis DEVENTER, 7415 EH, Netherlands Completed Private Practice Dr MK Dhanjee Newcastle, 2940, South Africa Completed Randles Road Medical Centre Durban, 4091, South Africa Completed Newkwa Medical Centre Durban, 4037, South Africa Completed Parklands Medical Centre - Durban Durban, 4091, South Africa Primary Outcome Maintenance of erection in men with ED, Improvement of their female partners sexual quality of life date_range Time Frame: 12 weeks enhanced_encryption Safety Issue: no Secondary Outcome SEP3 at weeks 4, 12, 18, and 24 of treatment compared to placebo date_range Time Frame: 24 weeks enhanced_encryption Safety Issue: no Additional Subject Diary questions at weeks 4, 12, 18, and 24, LOCF, and over entire treatment period compared to placebo date_range Time Frame: 24 weeks enhanced_encryption Safety Issue: no Global confidence question (GCQ) at weeks 12, and 24 of treatment compared to placebo. IIEF, TSS, mSLQQ-QOL, Partnership questionnaire (PFB20) date_range Time Frame: 24 weeks enhanced_encryption Safety Issue: no Trial design A randomized, double blind, parallel group study of vardenafil flexible dose versus placebo in males with erectile dysfunction and their female partners sexual quality of life.

Ghi chú

Vardenafil's indications and contraindications are the same as with other PDE5 inhibitors; it is closely related in function to sildenafil citrate (Viagra) and tadalafil (Cialis). The difference between the vardenafil molecule and sildenafil citrate is a nitrogen atom's position and the change of sildenafil's piperazine ring methyl group to an ethyl group. Tadalafil is structurally different from both sildenafil and vardenafil. Vardenafil's relatively short effective time is comparable to but somewhat longer than sildenafil's. PARTNER II Trial Type Interventional Intervention Type Drug Trial Purpose Treatment Allocation Randomized Blinding Double Blind Assignment Parallel Assignment Trial Arms 2 Additional Information Click here and search for drug information provided by the FDA.

Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.

• Bayer originally developed Vardenafil in the late 1990s.
• Approved by the FDA in 2003 for erectile dysfunction.
• Also studied for pulmonary arterial hypertension.

Click here to find information about studies related to Bayer Healthcare products conducted in Europe Click here to find results for studies related to Bayer Healthcare products. Sexual Encounter Profile Question 2 and 3 and International Index of Erectile Function - Erectile Function domaindate_rangeTime Frame:12 weeksenhanced_encryptionnoSafety Issue: Duration of erection leading to positive Sexual Encounter Profile Question 3date_rangeTime Frame:12 weeksenhanced_encryptionnoSafety Issue: Safety and tolerabilitydate_rangeTime Frame:12 weeksenhanced_encryptionyesSafety Issue: Other patient diary based variablesdate_rangeTime Frame:12 weeksenhanced_encryptionnoSafety Issue: The change from baseline in Fansworth Munsell (FM) 100 test total error score (TES) in both the left and right eyes for vardenafil treated subjects as compared to placebodate_rangeTime Frame:8 weeksenhanced_encryptionNoneSafety Issue: The change from baseline in Electroretinogram (ERG) as measured by amplitude and implicit time of b wave in both the left and right eyes for vardenafil treated subjects as compared to placebodate_rangeTime Frame:8 weeksenhanced_encryptionNoneSafety Issue: Change in the FM-100 total error score from baseline at approximately 6 hours and 24 hours post dosedate_rangeTime Frame:8 weeksenhanced_encryptionNoneSafety Issue: Safety and tolerability of 20 mg vardenafil after at least 15 oral doses of 20 mg vardenafil or placebo (dosed over approximately 8 weeks)date_rangeTime Frame:8 ceridaviescampaigner co uk weeksenhanced_encryptionNoneSafety Issue: ERG and FM-100 total error score from baseline at approximately 2 hours following one dose of sildenafil 200 mgdate_rangeTime Frame:8 weeksenhanced_encryptionNoneSafety Issue: The Bayer Clinical Trials Registry and Results Database website contains information on clinical trials sponsored by Bayer, and is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. The information contained within the website is not intended to replace the advice of a healthcare professional and should not be considered as a recommendation. Patients should always seek medical advice before making any decisions on their treatment.

Healthcare professionals should always refer to the specific labeling information approved for the patient's country or region. The data on the website should not be considered as prescribing advice.

The data on the website may differ from published or presented data and are a reflection of the limited information provided there. The results from a single trial need to be considered in the context of the full clinical research for a drug.

Key Participants Requirements

Sexual Encounter Profile Question 2 and 3 and International Index of Erectile Function - Erectile Function domaindate_rangeTime Frame:12 weeksenhanced_encryptionnoSafety Issue: Duration of erection leading to positive Sexual Encounter Profile Question 3date_rangeTime Frame:12 weeksenhanced_encryptionnoSafety Issue: Safety and tolerabilitydate_rangeTime Frame:12 weeksenhanced_encryptionyesSafety Issue: Other patient diary based variablesdate_rangeTime Frame:12 weeksenhanced_encryptionnoSafety Issue: The change from baseline in Fansworth Munsell (FM) 100 test total error score (TES) in both the left and right eyes for vardenafil treated subjects as compared to placebodate_rangeTime Frame:8 weeksenhanced_encryptionNoneSafety Issue: The change from baseline in Electroretinogram (ERG) as measured by amplitude and implicit time of b wave in both the left and right eyes for vardenafil treated subjects as compared to placebodate_rangeTime Frame:8 weeksenhanced_encryptionNoneSafety Issue: Change in the FM-100 total error score from baseline at approximately 6 hours and 24 hours post dosedate_rangeTime Frame:8 weeksenhanced_encryptionNoneSafety Issue: Safety and tolerability of 20 mg vardenafil after at least 15 oral doses of 20 mg vardenafil or placebo (dosed over approximately 8 weeks)date_rangeTime Frame:8 ceridaviescampaigner co uk weeksenhanced_encryptionNoneSafety Issue: ERG and FM-100 total error score from baseline at approximately 2 hours following one dose of sildenafil 200 mgdate_rangeTime Frame:8 weeksenhanced_encryptionNoneSafety Issue: The Bayer Clinical Trials Registry and Results Database website contains information on clinical trials sponsored by Bayer, and is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. The information contained within the website is not intended to replace the advice of a healthcare professional and should not be considered as a recommendation. Patients should always seek medical advice before making any decisions on their treatment. Healthcare professionals should always refer to the specific labeling information approved for the patient's country or region. The data on the website should not be considered as prescribing advice.

Pharmacokinetics and Pharmacodynamics

The data on the website may differ from published or presented data and are a reflection of the limited information provided there. The results from a single trial need to be considered in the context of the full clinical research for a drug. All reasonable precautions have been taken to ensure the accuracy, security and confidentiality of the information available through the site. Bayer may amend the information at any time without notice. aDepartment of Urology and Center for Sexual and Reproductive Health, Aristotle University of Thessaloniki, 77 Mitropoleos str., 546 22 Thessaloniki, Greece DOI: 10.1016/j.eururo.2004.01.014 External LinkAlso available on ScienceDirect External Link Vardenafil for Treatment of Men With Erectile Dysfunction: Efficacy and Safety in a Randomized, Double-Blind, Placebo-Controlled Trial Safety and efficacy of vardenafil for the treatment of men with erectile dysfunction after radical retropubic prostatectomy Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study Influence of age on the efficacy and safety of vardenafil, a novel phosphodiesterase-5 inhibitor, for the treatment of erectile dysfunction The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction Achieving treatment optimization with sildenafil citrate (Viagra(R)) in patients with erectile dysfunction The potential value of erectile dysfunction inquiry and management Hellstrom, W.

Contraindications and Warnings

∙ Gittelman, M. ∙ Karlin, G. ..., on behalf of the Vardenafil Study Group Sustained efficacy and tolerability of vardenafil (Levitra®), a highly potent, selective phosphodiesterase-5 inhibitor, in men with erectile dysfunction: results of a randomized, double-blind, 26-week placebo-controlled pivotal trial Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil. Wie wirksam sind die PDE-5 Hemmstoffe When an erection alone is not enough: biopsychosocial obstacles to lovemaking Incidence and determinants of sildenafil (dis)continuation: the Dutch cohort of sildenafil users Drop out reason in responders to sildenafil "Effects of vardenafil administration on intravaginal ejaculatory latency time in men with lifelong premature ejaculation". ↑ Schools of Pharmacy (Glen L. All reasonable precautions have been taken to ensure the accuracy, security and confidentiality of the information available through the site.

• Bayer Vardenafil can improve quality of life for men with ED.
• The medication works best in conjunction with psychological support if needed.
• It is not approved for enhancing athletic performance.
• The drug's duration can be affected by age and health.
• Some patients may require dose adjustments for optimal results.
• Vardenafil may interact with antibiotics and antifungals.
• It is part of a comprehensive approach including lifestyle management.
• The patent and marketing rights belong to Bayer.
• Always inform your doctor about any side effects experienced during treatment.

Bayer may amend the information at any time without notice. aDepartment of Urology and Center for Sexual and Reproductive Health, Aristotle University of Thessaloniki, 77 Mitropoleos str., 546 22 Thessaloniki, Greece DOI: 10.1016/j.eururo.2004.01.014 External LinkAlso available on ScienceDirect External Link Vardenafil for Treatment of Men With Erectile Dysfunction: Efficacy and Safety in a Randomized, Double-Blind, Placebo-Controlled Trial Safety and efficacy of vardenafil for the treatment of men with erectile dysfunction after radical retropubic prostatectomy Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study Influence of age on the efficacy and safety of vardenafil, a novel phosphodiesterase-5 inhibitor, for the treatment of erectile dysfunction The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction Achieving treatment optimization with sildenafil citrate (Viagra(R)) in patients with erectile dysfunction The potential value of erectile dysfunction inquiry and management Hellstrom, W.

Where to participate

Stimmel, Pharm.D., and Mary A. Gutierrez, Pharm.D.) and Medicine (Glen L. Stimmel, Pharm.D. ), University of Southern California, Los Angeles, California. "Counseling Patients About Sexual Issues: Drug-Induced Priapism".

Efficacy in Clinical Trials

Class Antifibrotics; Antihypertensives; Bronchodilators; Erectile dysfunction therapies; Imidazoles; Piperazines; Small molecules; Sulfones; Triazines Mechanism of Action Type 5 cyclic nucleotide phosphodiesterase inhibitors Orphan Drug Status NoOrphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases. Orphan vidalista 20mg uk designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases. The FDA has approved a new generic equivalent to Levitra for erectile dysfunction. Officials with the FDA have approved the Abbreviated New Drug Application (ANDA) for Alembic’s Vardenafil Hydrochloride Tablets, 2.5 mg, 5 mg, 10 mg, and 20 mg. The drug is indicated for the treatment of erectile dysfunction.1 According to Alembic, the approved ANDA is therapeutically equivalent to Bayer’s vardenafil hydrochloride (Levitra) tablets, 2.5 mg, 5 mg, 10 mg, and 20 mg.1 Vardenafil hydrochloride tablets were developed by GlaxoSmithKline and Bayer, and approved by the FDA in 2003.2 Vardenafil hydrochloride tablet have an estimated market size of $35 billion for 12 months ending June 2020, according to data obtained by Alembic.1 Alembic Pharmaceuticals Receives USFDA Final Approval for Vardenafil Hydrochloride Tablets, 2.5 mg (base), 5 mg (base), 10 mg (base), and 20 mg (base) [news release].

Dosing Guidelines and Administration

Some Branded Drugs Going Generic in 2018. You'll soon need a free account to access DrugBank. Core data resources will remain freely available. Explore without interruption, create a free account. Sexual Encounter Profile (SEP), questions 2 and 3date_rangeTime Frame:12 weeksenhanced_encryptionnoSafety Issue: International Index of Erectile Function (IIEF) - EF (Erectile Function) domaindate_rangeTime Frame:12 weeksenhanced_encryptionnoSafety Issue: Global Assessment Questionnaire (GAQ)date_rangeTime Frame:12 weeksenhanced_encryptionnoSafety Issue: Safety and tolerabilitydate_rangeTime Frame:12 weeksenhanced_encryptionyesSafety Issue: Vardenafil, sold under the brand name Levitra among others, is a medication that is used for treating erectile dysfunction. ∙ Gittelman, M. ∙ Karlin, G. ..., on behalf of the Vardenafil Study Group Sustained efficacy and tolerability of vardenafil (Levitra®), a highly potent, selective phosphodiesterase-5 inhibitor, in men with erectile dysfunction: results of a randomized, double-blind, 26-week placebo-controlled pivotal trial Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil. Wie wirksam sind die PDE-5 Hemmstoffe When an erection alone is not enough: biopsychosocial obstacles to lovemaking Incidence and determinants of sildenafil (dis)continuation: the Dutch cohort of sildenafil users Drop out reason in responders to sildenafil "Effects of vardenafil administration on intravaginal ejaculatory latency time in men with lifelong premature ejaculation". ↑ Schools of Pharmacy (Glen L. Stimmel, Pharm.D., and Mary A.

Gutierrez, Pharm.D.) and Medicine (Glen L.

• Patients with severe kidney or liver impairment need dose adjustment.
• Not recommended for those with severe heart conditions.
• Caution in patients with retinitis pigmentosa.

Stimmel, Pharm.D. ), University of Southern California, Los Angeles, California. "Counseling Patients About Sexual Issues: Drug-Induced Priapism". Class Antifibrotics; Antihypertensives; Bronchodilators; Erectile dysfunction therapies; Imidazoles; Piperazines; Small molecules; Sulfones; Triazines Mechanism of Action Type 5 cyclic nucleotide phosphodiesterase inhibitors Orphan Drug Status NoOrphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases. Orphan vidalista 20mg uk designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases. The FDA has approved a new generic equivalent to Levitra for erectile dysfunction. Officials with the FDA have approved the Abbreviated New Drug Application (ANDA) for Alembic’s Vardenafil Hydrochloride Tablets, 2.5 mg, 5 mg, 10 mg, and 20 mg. The drug is indicated for the treatment of erectile dysfunction.1 According to Alembic, the approved ANDA is therapeutically equivalent to Bayer’s vardenafil hydrochloride (Levitra) tablets, 2.5 mg, 5 mg, 10 mg, and 20 mg.1 Vardenafil hydrochloride tablets were developed by GlaxoSmithKline and Bayer, and approved by the FDA in 2003.2 Vardenafil hydrochloride tablet have an estimated market size of $35 billion for 12 months ending June 2020, according to data obtained by Alembic.1 Alembic Pharmaceuticals Receives USFDA Final Approval for Vardenafil Hydrochloride Tablets, 2.5 mg (base), 5 mg (base), 10 mg (base), and 20 mg (base) [news release].

Primary Outcome

Dr. E. U. Krohn Hamburg, 22177, Germany Completed Praxis Hr. Dr.

Experts Discuss the Potential Role of GLP-1 Receptor Agonists in Breast Cancer Outcomes and Survivorship Care

F. Matthes Leisnig, 04703, Germany Completed Praxis Fr. Dr. W. Pohl Dresden, 01129, Germany Completed Praxis Drs.

Indications for Use

Careggi Firenze, 50139, Italy Completed Hospital Policlínico de Vigo - Clínica Povisa Vigo, 36211, Spain Completed Hospital Universitario de Canarias La Laguna, 38320, Spain Completed Hospital General Universitario de Alicante Alicante, 03010, Spain Completed Hospital Fundació Puigvert Barcelona, 08025, Spain Completed CAP Sarrià Barcelona, 08034, Spain Completed CHU de Liège LIEGE, 4000, Belgium Completed Dr Bongaerts - Dr Denier GENK, 3600, Belgium Completed Medisch Spectrum Twente, Locatie Ariensplein ENSCHEDE, 7511 JX, Netherlands Completed Deventer Ziekenhuis DEVENTER, 7415 EH, Netherlands Completed Private Practice Dr MK Dhanjee Newcastle, 2940, South Africa Completed Randles Road Medical Centre Durban, 4091, South Africa Completed Newkwa Medical Centre Durban, 4037, South Africa Completed Parklands Medical Centre - Durban Durban, 4091, South Africa Primary Outcome Maintenance of erection in men with ED, Improvement of their female partners sexual quality of life date_range Time Frame: 12 weeks enhanced_encryption Safety Issue: no Secondary Outcome SEP3 at weeks 4, 12, 18, and 24 of treatment compared to placebo date_range Time Frame: 24 weeks enhanced_encryption Safety Issue: no Additional Subject Diary questions at weeks 4, 12, 18, and 24, LOCF, and over entire treatment period compared to placebo date_range Time Frame: 24 weeks enhanced_encryption Safety Issue: no Global confidence question (GCQ) at weeks 12, and 24 of treatment compared to placebo. IIEF, TSS, mSLQQ-QOL, Partnership questionnaire (PFB20) date_range Time Frame: 24 weeks enhanced_encryption Safety Issue: no Trial design A randomized, double blind, parallel group study of vardenafil flexible dose versus placebo in males with erectile dysfunction and their female partners sexual quality of life. PARTNER II Trial Type Interventional Intervention Type Drug Trial Purpose Treatment Allocation Randomized Blinding Double Blind Assignment Parallel Assignment Trial Arms 2 Additional Information Click here and search for drug information provided by the FDA. Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product. Click here to find information about studies related to Bayer Healthcare products conducted in Europe Click here to find results for studies related to Bayer Healthcare products. Some Branded Drugs Going Generic in 2018. You'll soon need a free account to access DrugBank.

Trial purpose

Core data resources will remain freely available. Explore without interruption, create a free account. Sexual Encounter Profile (SEP), questions 2 and 3date_rangeTime Frame:12 weeksenhanced_encryptionnoSafety Issue: International Index of Erectile Function (IIEF) - EF (Erectile Function) domaindate_rangeTime Frame:12 weeksenhanced_encryptionnoSafety Issue: Global Assessment Questionnaire (GAQ)date_rangeTime Frame:12 weeksenhanced_encryptionnoSafety Issue: Safety and tolerabilitydate_rangeTime Frame:12 weeksenhanced_encryptionyesSafety Issue: Vardenafil, sold under the brand name Levitra among others, is a medication that is used for treating erectile dysfunction. Vardenafil's indications and contraindications are the same as with other PDE5 inhibitors; it is closely related in function to sildenafil citrate (Viagra) and tadalafil (Cialis). The difference between the vardenafil molecule and sildenafil citrate is a nitrogen atom's position and the change of sildenafil's piperazine ring methyl group to an ethyl group. Tadalafil is structurally different from both sildenafil and vardenafil. Vardenafil's relatively short effective time is comparable to but somewhat longer than sildenafil's.